Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 …

Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago ONCODESIGNPosted on: 21 Oct 15 Regulatory News: ONCODESIGN (Paris:ALONC) (FR0011766229 РALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, will present today with Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty-driven pharmaceutical company, the discovery and characterization of ODS2005294, a novel LRRK2 inhibitor they jointly discovered in a research collaboration started in January 2012. The molecule will be presented at the 45th annual meeting of the Society for Neurosciences that is taking place October 17-21 in Chicago, IL; this leading global meeting for presentation of novel discoveries in neuroscience is attended by over 30,000 experts…


Link to Full Article: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 …